Meeting
2022 ASCO Annual Meeting
Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA).
Authors
Atara Isaiah Ntekim
Department of Radiation Oncology, Oyo, Nigeria
Atara Isaiah Ntekim , Omoba Temitayo Adeniji-Sofoluwe , Anthonia Sowunmi , Ayorinde Folasire , Olalekan Olasehinde , AbdulRazzak Lawaal , Thomas Olajide , Foluso Omodele , Omolara A. Fatiregun , Ayodele Sanni , Mustapha Ajani , Olayinka Kotila , Akinwunmi O. Komolafe , Alabi AO , Popoola Abiodun Olaniyi , Chioma Christie Asuzu , Adetola Daramola , Chinedum Peace Babalola , Theodore Karrison , Olufunmilayo I. Olopade
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT03879577
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS622)
DOI
10.1200/JCO.2022.40.16_suppl.TPS622
Abstract #
TPS622
Poster Bd #
385b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
First Author: Hong-Fei Gao
Poster
2015 ASCO Annual Meeting
Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).
First Author: Christian Jackisch
Poster
2013 ASCO Annual Meeting
Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis.
First Author: Christine Brunner
Poster
2019 ASCO Annual Meeting
Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.
First Author: Theodoros Foukakis